These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9205691)

  • 21. [-Skin eruption after the first dose of antitubercular quadri-therapy: consideration of pyrazinamide-].
    Olivier C; Radal M; Mazaud S; Jonville-Béra AP; Martel C; Autret E
    Arch Pediatr; 1998 Mar; 5(3):289-90. PubMed ID: 10327997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A case of tuberculous meningitis complicated with multiple drug hypersensitivity to antituberculosis agents].
    Arai M
    Rinsho Shinkeigaku; 2015; 55(2):123-5. PubMed ID: 25746078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple Drug Hypersensitivity Syndrome to Antituberculosis Drugs: A Case Report.
    Carneiro-Leão L; Gomes I; Freitas C; Costa E Silva M; Viseu R; Cernadas J
    J Investig Allergol Clin Immunol; 2020; 30(1):70-71. PubMed ID: 31530510
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
    Danckwerts MP; Ebrahim S; Pillay V
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hepatic tuberculosis: a case with pseudotumours form].
    Sève P; Boibieux A; Biron F; Bouhour D; Rode A; Bancel B; Chidiac C; Peyramond D
    Ann Med Interne (Paris); 1998 Oct; 149(6):386-8. PubMed ID: 9853049
    [No Abstract]   [Full Text] [Related]  

  • 26. Telacebec (Q203), a New Antituberculosis Agent.
    de Jager VR; Dawson R; van Niekerk C; Hutchings J; Kim J; Vanker N; van der Merwe L; Choi J; Nam K; Diacon AH
    N Engl J Med; 2020 Mar; 382(13):1280-1281. PubMed ID: 32212527
    [No Abstract]   [Full Text] [Related]  

  • 27. Pyrazinamide serum levels in childhood tuberculosis.
    Thee S; Detjen A; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Granulomatous lesion on the face successfully treated with antitubercular therapy.
    Ricart JM; Martín JM; Renau A; Pérez J
    Dermatol Online J; 2010 Sep; 16(9):13. PubMed ID: 20875334
    [No Abstract]   [Full Text] [Related]  

  • 29. Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens.
    Lincoln T; Brannan GL; Lynch V; Conklin TJ; Clancey T; Rose DN; Tuthill RJ
    Int J Tuberc Lung Dis; 2004 Mar; 8(3):306-11. PubMed ID: 15139468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tuberculosis treatment: dangerous regimens?
    Rieder HL; Arnadottir T; Trébucq A; Enarson DA
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):1-3. PubMed ID: 11263509
    [No Abstract]   [Full Text] [Related]  

  • 31. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects.
    Qurrat-ul-Ain ; Sharma S; Khuller GK; Garg SK
    J Antimicrob Chemother; 2003 Apr; 51(4):931-8. PubMed ID: 12654730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation.
    Milán-Segovia RC; Domínguez-Ramírez AM; Jung-Cook H; Magaña-Aquino M; Romero-Méndez MC; Medellín-Garibay SE; Vigna-Pérez M; Romano-Moreno S
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1454-60. PubMed ID: 20937187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
    Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
    Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Shock and cerebral infarct after rifampin re-exposure in a patient infected with human immunodeficiency virus.
    Martínez E; Collazos J; Mayo J
    Clin Infect Dis; 1998 Nov; 27(5):1329-30. PubMed ID: 9827298
    [No Abstract]   [Full Text] [Related]  

  • 35. Isoniazid induced gynaecomastia: a case report.
    Garg R; Vaibhav ; Mehra S; Prasad R
    Indian J Tuberc; 2009 Jan; 56(1):51-4. PubMed ID: 19402273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-in-one TB drug approved.
    Posit Aware; 1995; ():5. PubMed ID: 11362378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy].
    Zhu L; Yan B; Ma W
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Nov; 21(11):645-7. PubMed ID: 11477887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is the treatment of WHO category I tuberculosis with 2HRZE/6HE a defensible practice?
    Long R; Scalcini M
    Int J Tuberc Lung Dis; 1999 Sep; 3(9):747-8. PubMed ID: 10488879
    [No Abstract]   [Full Text] [Related]  

  • 40. [The effects of antituberculosis drugs on the pharmacokinetics of digitoxin (author's transl)].
    Peters U; Hausamen TU; Grosse-Brockhoff F
    Dtsch Med Wochenschr; 1974 Nov; 99(47):2381-6. PubMed ID: 4426257
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.